以岭药业
(002603)
| 流通市值：196.67亿 | | | 总市值：238.74亿 |
| 流通股本：13.76亿 | | | 总股本：16.71亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,365,441,001.17 | 4,604,485,816.89 | 2,522,632,691.84 | 10,318,312,851.48 |
| 营业收入 | 6,365,441,001.17 | 4,604,485,816.89 | 2,522,632,691.84 | 10,318,312,851.48 |
| 二、营业总成本 | 5,723,859,252.05 | 3,978,871,341.64 | 2,163,331,046.01 | 8,719,196,279.82 |
| 营业成本 | 2,966,689,927.87 | 2,147,158,224.84 | 1,224,060,652.16 | 4,407,809,142.42 |
| 税金及附加 | 92,543,140.09 | 71,956,228.65 | 44,322,265.2 | 135,127,541.73 |
| 销售费用 | 1,672,009,793.12 | 1,077,919,466.42 | 567,763,691 | 2,704,662,350.69 |
| 管理费用 | 395,046,421.77 | 271,382,273.04 | 138,156,271.01 | 592,041,815.39 |
| 研发费用 | 571,912,835.78 | 393,289,796.04 | 180,592,474.56 | 853,187,332.74 |
| 财务费用 | 25,657,133.42 | 17,165,352.65 | 8,435,692.08 | 26,368,096.85 |
| 其中:利息费用 | 28,465,206.58 | 20,040,003.71 | 9,553,332.39 | 38,900,732.82 |
| 其中:利息收入 | 5,607,750.08 | 4,070,555.44 | 2,076,674.99 | 16,094,073.14 |
| 加:公允价值变动收益 | 38,863,277.79 | 25,905,930.58 | 12,952,965.31 | 39,353,763.88 |
| 加:投资收益 | 501,146.91 | 927,290.25 | 3,814,579.74 | 25,950,359.15 |
| 资产处置收益 | -1,763,045.54 | -982,250.89 | -58,223.56 | -819,304.68 |
| 资产减值损失(新) | -4,677,546.02 | -3,118,364.01 | -1,559,182.01 | -35,358,052.07 |
| 信用减值损失(新) | -17,641,197.58 | -6,707,184.39 | -3,377,856.94 | -23,698,245.04 |
| 其他收益 | 46,269,378.55 | 29,318,935.88 | 20,320,333.83 | 175,282,436.35 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 703,133,763.23 | 670,958,832.67 | 391,394,262.2 | 1,779,827,529.25 |
| 加:营业外收入 | 2,499,457.21 | 1,198,980.25 | 826,483.31 | 8,439,586.51 |
| 减:营业外支出 | 33,524,829.83 | 28,835,737.5 | 23,765,138.03 | 104,055,756.16 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 672,108,390.61 | 643,322,075.42 | 368,455,607.48 | 1,684,211,359.6 |
| 减:所得税费用 | 123,021,537.87 | 116,695,700.53 | 66,535,908.87 | 339,908,683.82 |
| 六、净利润 | 549,086,852.74 | 526,626,374.89 | 301,919,698.61 | 1,344,302,675.78 |
| 持续经营净利润 | 549,086,852.74 | 526,626,374.89 | 301,919,698.61 | 1,344,302,675.78 |
| 归属于母公司股东的净利润 | 554,776,843.41 | 530,457,109.15 | 303,927,918.74 | 1,352,379,242.86 |
| 少数股东损益 | -5,689,990.67 | -3,830,734.26 | -2,008,220.13 | -8,076,567.08 |
| (一)基本每股收益 | 0.33 | 0.32 | 0.18 | 0.81 |
| (二)稀释每股收益 | 0.33 | 0.32 | 0.18 | 0.81 |
| 八、其他综合收益 | 551,883.75 | 20,576.61 | -33,169.55 | 604,594.09 |
| 归属于母公司股东的其他综合收益 | 551,883.75 | 20,576.61 | -33,169.55 | 604,594.09 |
| 九、综合收益总额 | 549,638,736.49 | 526,646,951.5 | 301,886,529.06 | 1,344,907,269.87 |
| 归属于母公司股东的综合收益总额 | 555,328,727.16 | 530,477,685.76 | 303,894,749.19 | 1,352,983,836.95 |
| 归属于少数股东的综合收益总额 | -5,689,990.67 | -3,830,734.26 | -2,008,220.13 | -8,076,567.08 |
| 公告日期 | 2024-10-29 | 2024-08-28 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |